Experts Debate: Optimal Approaches to the Treatment of Multiple Myeloma

This webcast is not certified for credit

Release Date: January 15, 2021
Expiration Date: January 15, 2022

Activity Overview
Given the recent approval of immunotherapies for the treatment of patients with multiple myeloma (MM), as well as the associated volume of emerging data of investigational agents, it is critical that oncologists and hematologists be able to evaluate the benefits of these agents, select appropriate patients for therapy or clinical trials, and prevent and manage AEs. This webcast will cover
topics on treating patients with high-risk smoldering, transplant and optimal approaches to BCMA. 

Target Audience
The target audience for this activity is community and academic medical oncologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with MM.

Learning Objectives
After participating in this activity, participants should be better able to:

  • Evaluate clinical trial results of frontline treatment options that are available for the treatment of patients with newly diagnosed MM
  • Review maintenance therapy strategies for patients with MM that are eligible to receive this type of therapy
  • Assess treatment approaches and sequencing of therapy for patients with relapsed and/or refractory MM
  • Optimize approaches to manage treatment-related adverse events that may occur during the treatment of patients with MM
  • Discuss clinical trials results that are investigating emerging novel agents in patients with MM
Method of Participation
There are no fees for participating in this activity

Expert Debates
Should We be Treating Patients with High-Risk Smoldering MM?  
Pieter Sonneveld, MD, PhD vs. Peter Voorhees, MD

Is There Sufficient Data to Include Antibodies in Frontline Regimens?
Pieter Sonneveld, MD, PhD vs. Peter Voorhees, MD

Transplant vs No Transplant
Kenneth Anderson, MD vs. Pieter Sonneveld, MD, PhD

Should Antibodies be a Standard Agent Included in Regimens for First Relapse?
Sagar Lonial, MD, FACP vs. Kenneth Anderson, MD

What Emerging Class of Agents Should Be Used in Relapsed/Refractory MM Upon Approval?
  • Antibody-Drug Conjugates/Peptide-Drug Conjugates – Sagar Lonial, MD, FACP
  • Bispecific Antibodies – Peter Voorhees, MD
  • CAR T-cell – Kenneth Anderson, MD

Panel Discussion and Audience Q&A 
Sagar Lonial, MD, FACP
Chief Medical Officer
Winship Cancer Institute of Emory University
Professor and Chair, Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Emory University School of Medicine
Atlanta, Georgia

Consulting Fees: Amgen Inc., Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline LLC, Janssen Oncology, Karyopharm Therapeutics, Merck & Co., Novartis

Kenneth Anderson, MD
Kraft Family Professor of Medicine
Harvard Medical School
Program Director
Jerome Lipper Multiple Myeloma Center and Lebow Institute for Myeloma Therapeutics
Dana-Farber Cancer Institute
Boston, Massachusetts

Consultant Fees: Bristol Myers Squibb, Gilead Sciences, Inc., Janssen Pharmaceuticals, Inc., Millennium: The Takeda Oncology Company, Precision Biosciences, Sanofi, Tolero Pharmaceuticals, Inc.

Ownership Interest: Oncopeptides, C4 Therapeutics (Scientific Founder)

Pieter Sonneveld, MD
Department Head and Professor of Hematology
Erasmus MC Cancer Institute
University Medical Center Rotterdam
Rotterdam, Holland, Netherlands

Employment: Hematology, Erasmus MC Cancer Institute, Rotterdam
Discussion of off-label drug use: Not Applicable
Research support:  Amgen, Celgene, Janssen, Karyopharm, SkylineDx
Advisory Boards: Amgen, BMS/Celgene, Janssen, Karyopharm, Oncopeptides, Skyline Dx, Seattle Genetics
Chair European Myeloma Network
Chair Hovon Myeloma Working Group

Peter Voorhees, MD
Professor of Medicine
Director, Clinical Operations and Outreach for Hematologic Malignancies
Member, Plasma Cell Disorders Program
Department of Hematologic Oncology and Blood Disorders
Levine Cancer Institute, Atrium Health
Charlotte, North Carolina

Consulting Fees: Bristol Myers Squibb, GlaxoSmithKline LLC, Novartis, Oncopeptides

This activity is supported by independent educational grants from GlaxoSmithKline, Janssen, and Oncopeptides.

Technical Requirements

This activity is best experienced using the most current browser (or one back) of Firefox, Chrome, Safari, Internet Explorer, or Microsoft Edge. For all activities featuring audio you must have a sound card and speakers. To view graphic images and references that appear in separate "pop-up" windows, you must have JavaScript and session cookies enabled on your computer. Adobe Acrobat Reader may be required for certain activities.

Select the Continue button below to begin. You may return later if you are unable to complete the activity at this time.